<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27709762</article-id><article-id pub-id-type="pmc">5299522</article-id><article-id pub-id-type="doi">10.1111/dom.12803</article-id><article-id pub-id-type="publisher-id">DOM12803</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Pharmacological properties of faster&#x02010;acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double&#x02010;blind, crossover trial</article-title><alt-title alt-title-type="right-running-head">HEISE <sc>et al.</sc></alt-title><alt-title alt-title-type="left-running-head">H<sc>eise et al.</sc></alt-title></title-group><contrib-group><contrib id="dom12803-cr-0001" contrib-type="author" corresp="yes"><name><surname>Heise</surname><given-names>Tim</given-names></name><degrees>MD</degrees><address><email>tim.heise@profil.com</email></address><xref ref-type="aff" rid="dom12803-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12803-cr-0002" contrib-type="author"><name><surname>Zijlstra</surname><given-names>Eric</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12803-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12803-cr-0003" contrib-type="author"><name><surname>Nosek</surname><given-names>Leszek</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12803-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12803-cr-0004" contrib-type="author"><name><surname>Rikte</surname><given-names>Tord</given-names></name><degrees>LicEng</degrees><xref ref-type="aff" rid="dom12803-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12803-cr-0005" contrib-type="author"><name><surname>Haahr</surname><given-names>Hanne</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12803-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="dom12803-aff-0001"><label><sup>1</sup></label><institution>Profil Institut f&#x000fc;r Stoffwechselforschung GmbH</institution><named-content content-type="city">Neuss</named-content><country country="DE">Germany</country></aff><aff id="dom12803-aff-0002"><label><sup>2</sup></label><institution>Novo Nordisk A/S</institution><named-content content-type="city">S&#x000f8;borg</named-content><country country="DK">Denmark</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Corresponding Author</bold>: Tim Heise, Profil Institut f&#x000fc;r Stoffwechselforschung GmbH, Hellersbergstrasse 9, D&#x02010;41460 Neuss, Germany (<email>tim.heise@profil.com</email>).</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2017</year></pub-date><volume>19</volume><issue>2</issue><issue-id pub-id-type="doi">10.1111/dom.2017.19.issue-2</issue-id><fpage>208</fpage><lpage>215</lpage><history><date date-type="received"><day>06</day><month>7</month><year>2016</year></date><date date-type="rev-recd"><day>24</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>28</day><month>9</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-19-208.pdf"/><abstract id="dom12803-abs-0001"><sec id="dom12803-sec-0001"><title>Aim</title><p id="dom12803-para-0001">To evaluate the pharmacological characteristics of faster&#x02010;acting insulin aspart (faster aspart) compared with insulin aspart (<styled-content style="fixed-case">IAsp</styled-content>) during continuous subcutaneous insulin infusion (<styled-content style="fixed-case">CSII</styled-content>).</p></sec><sec id="dom12803-sec-0002"><title>Methods</title><p id="dom12803-para-0002">In this randomized, double&#x02010;blind, crossover trial, 48 men and women aged 18 to 64 years with type 1 diabetes mellitus (<styled-content style="fixed-case">T1DM</styled-content>) received faster aspart and <styled-content style="fixed-case">IAsp</styled-content> as a 0.15 U/kg bolus dose via <styled-content style="fixed-case">CSII</styled-content>, on top of a basal rate (0.02 U/kg/h), in a glucose clamp setting (target 5.5 mmol/L).</p></sec><sec id="dom12803-sec-0003"><title>Results</title><p id="dom12803-para-0003">After a <styled-content style="fixed-case">CSII</styled-content> bolus dose, the pharmacokinetic/pharmacodynamic profiles for faster aspart were left&#x02010;shifted compared with those for <styled-content style="fixed-case">IAsp</styled-content>. For faster aspart vs <styled-content style="fixed-case">IAsp</styled-content>, the early glucose&#x02010;lowering effect (area under the curve for glucose infusion rate [<styled-content style="fixed-case">GIR</styled-content>]<sub>0&#x02010;30min</sub>) was approximately 2&#x02010;fold higher (least squares means 24.9 vs 11.4 mg/kg; estimated ratio faster aspart/<styled-content style="fixed-case">IAsp</styled-content> 2.18, 95% confidence interval [CI] [1.33; 5.04]; <styled-content style="italic-in-any-context">P</styled-content> = .002), onset of glucose&#x02010;lowering effect (time to early 50% of maximum <styled-content style="fixed-case">GIR</styled-content>) occurred 11.1 minutes earlier (41.1 vs 52.3 minutes; 95% <styled-content style="fixed-case">CI</styled-content> faster aspart &#x02013; <styled-content style="fixed-case">IAsp</styled-content> [&#x02212;15.4; &#x02212;6.9]; <styled-content style="italic-in-any-context">P</styled-content>&#x0003c;.001), and offset of glucose&#x02010;lowering effect (time to late 50% of maximum <styled-content style="fixed-case">GIR</styled-content>) occurred 24.0 minutes earlier (214.7 vs 238.7 minutes; 95% CI [&#x02212;38.9; &#x02212;9.1]; <styled-content style="italic-in-any-context">P</styled-content>=.002). Likewise, significantly greater early exposure and significantly earlier onset and offset of exposure were observed for faster aspart vs <styled-content style="fixed-case">IAsp</styled-content>. Faster aspart and <styled-content style="fixed-case">IAsp</styled-content> were both well tolerated.</p></sec><sec id="dom12803-sec-0004"><title>Conclusions</title><p id="dom12803-para-0004">In patients with <styled-content style="fixed-case">T1DM</styled-content> using <styled-content style="fixed-case">CSII</styled-content>, faster aspart better mimics the endogenous prandial insulin secretion and action than does <styled-content style="fixed-case">IAsp</styled-content>. Faster aspart therefore has the potential to provide clinical benefits over current rapid&#x02010;acting insulins in the insulin pump setting.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12803-kwd-0001">insulin pump therapy</kwd><kwd id="dom12803-kwd-0002">pharmacodynamics</kwd><kwd id="dom12803-kwd-0003">pharmacokinetics</kwd><kwd id="dom12803-kwd-0004">type 1 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Novo Nordisk</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Boehringer Ingelheim</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Sanofi</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="8"/><word-count count="6018"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12803</meta-value></custom-meta><custom-meta><meta-name>header-id</meta-name><meta-value>dom12803-hdr-0001</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.5 mode:remove_FC converted:09.02.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom12803-cit-0000">
<string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zijlstra</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nosek</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rikte</surname>
<given-names>T</given-names>
</string-name> and <string-name>
<surname>Haahr</surname>
<given-names>H</given-names>
</string-name>. <article-title>Pharmacological properties of faster&#x02010;acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double&#x02010;blind, crossover trial</article-title>, <source>Diabetes Obes Metab</source>, <year>2017</year>;<volume>19</volume>(<issue>2</issue>):<fpage>208</fpage>&#x02013;<lpage>215</lpage>.<pub-id pub-id-type="pmid">27709762</pub-id></mixed-citation>
</p></notes><notes><fn-group id="dom12803-ntgp-0002a"><fn id="dom12803-note-0002a"><p>
<bold>Funding information</bold> This study was funded by Novo Nordisk.</p></fn></fn-group></notes></front><body><sec id="dom12803-sec-0005"><label>1</label><title>INTRODUCTION</title><p id="dom12803-para-0005">Postprandial glycaemic control plays a substantial role in reaching recommended glycated haemoglobin (HbA1c) goals in diabetes.<xref rid="dom12803-bib-0001" ref-type="ref">1</xref> Compared with regular human insulin (RHI), rapid&#x02010;acting insulin analogues (insulin aspart, insulin lispro and insulin glulisine) have provided better postprandial glucose control through an earlier and greater peak glucose&#x02010;lowering effect.<xref rid="dom12803-bib-0002" ref-type="ref">2</xref>, <xref rid="dom12803-bib-0003" ref-type="ref">3</xref> Nevertheless, absorption of current rapid&#x02010;acting insulins occurs too slowly to adequately replicate endogenous prandial insulin action.<xref rid="dom12803-bib-0004" ref-type="ref">4</xref>, <xref rid="dom12803-bib-0005" ref-type="ref">5</xref> Consequently, optimum postprandial glucose control remains a challenge in patients with diabetes.</p><p id="dom12803-para-0006">Continuous subcutaneous insulin infusion (CSII) is increasingly used in people with diabetes.<xref rid="dom12803-bib-0006" ref-type="ref">6</xref> CSII therapy is associated with improved glycaemic control, lower risk of hypoglycaemia and greater patient convenience compared with multiple daily injection therapy.<xref rid="dom12803-bib-0006" ref-type="ref">6</xref>, <xref rid="dom12803-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12803-bib-0008" ref-type="ref">8</xref> An insulin with a fast onset and fast offset of glucose&#x02010;lowering effect might be particularly important in a CSII setting to further improve postprandial glucose control without the risk of late post&#x02010;meal hypoglycaemia, and could also be a key factor in improving the performance of closed&#x02010;loop, artificial pancreas systems.<xref rid="dom12803-bib-0009" ref-type="ref">9</xref>
</p><p id="dom12803-para-0007">Faster&#x02010;acting insulin aspart (faster aspart) is insulin aspart in a new formulation that contains 2 well&#x02010;known excipients, niacinamide and L&#x02010;arginine. These are both listed in the US Food and Drug Administration inactive ingredient database, in products for injection, at higher concentrations than used in faster aspart.<xref rid="dom12803-bib-0010" ref-type="ref">10</xref> With faster aspart, niacinamide is responsible for faster initial absorption after subcutaneous administration and L&#x02010;arginine serves as a stabilizing agent. In subjects with type 1 diabetes mellitus (T1DM), faster aspart administered by subcutaneous injection had a twice&#x02010;as&#x02010;fast onset of appearance, a 2&#x02010;fold higher early exposure, and &#x0003e;50% greater early glucose&#x02010;lowering effect compared with insulin aspart.<xref rid="dom12803-bib-0011" ref-type="ref">11</xref>
</p><p id="dom12803-para-0008">Current rapid&#x02010;acting insulin analogues showed significant improvements over RHI in the pump setting with respect to glycaemic control and reduced hypoglycaemia.<xref rid="dom12803-bib-0012" ref-type="ref">12</xref>, <xref rid="dom12803-bib-0013" ref-type="ref">13</xref> Likewise, faster aspart may provide benefits over current rapid&#x02010;acting insulin analogues when used in a CSII regimen. In the present trial we evaluated, for the first time, the pharmacokinetic and pharmacodynamic properties of faster aspart compared with insulin aspart, using CSII in a euglycaemic clamp setting in subjects with T1DM.</p></sec><sec id="dom12803-sec-0006"><label>2</label><title>MATERIALS AND METHODS</title><sec id="dom12803-sec-0007"><label>2.1</label><title>Study design</title><p id="dom12803-para-0009">This was a randomized, single&#x02010;centre (Profil, Neuss, Germany), double&#x02010;blind, two&#x02010;period, crossover trial in people with T1DM. The trial protocol was reviewed and approved by the local health authority (Bundesinstitut f&#x000fc;r Arzneimittel und Medizinprodukte) and by an independent ethics committee (&#x000c4;rztekammer Nordrhein). The trial was performed in accordance with the Declaration of Helsinki and Good Clinical Practice, and registered at <ext-link ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01992588).</p></sec><sec id="dom12803-sec-0008"><label>2.2</label><title>Participants</title><p id="dom12803-para-0010">Eligible participants were men and women aged 18 to 64 years, who had been diagnosed with T1DM for &#x02265;12 months and treated with multiple daily insulin injections or CSII for &#x02265;12 months (total daily insulin dose &#x0003c;1.2 (I)U/kg/d and total daily bolus insulin dose &#x0003c;0.7 (I)U/kg/d), with HbA<sub>1c</sub> &#x02264;8.5%, body mass index (BMI) 18.5 to 28.0 kg/m<sup>2</sup>, and fasting C&#x02010;peptide &#x02264;0.3 nmol/L. Individuals were excluded if they had clinically significant concomitant diseases, abnormal values in clinical laboratory screening tests, were smokers, or were currently treated with drug(s) that may interfere with glucose metabolism. Written informed consent was obtained before initiation of any trial&#x02010;related activity.</p></sec><sec id="dom12803-sec-0009"><label>2.3</label><title>Procedures</title><p id="dom12803-para-0011">The trial consisted of a screening visit, 2 dosing visits separated by 3 to 12 days wash&#x02010;out, and a follow&#x02010;up visit.</p><p id="dom12803-para-0012">Participants were randomized (1:1) to receive faster aspart (100 U/mL; 3 mL Penfill; Novo Nordisk, Bagsv&#x000e6;rd, Denmark) followed by insulin aspart (NovoRapid; 100 U/mL; 3 mL Penfill; Novo Nordisk) or vice versa. The trial was double&#x02010;blind and the computer&#x02010;generated randomization scheme was prepared by Clinical Supplies Coordination, Novo Nordisk A/S (M&#x000e5;l&#x000f8;v, Denmark). Based on the randomization scheme, trial products were packed, in a double&#x02010;blind manner, in boxes specific for each randomization number before delivery to the clinical site.</p><p id="dom12803-para-0013">The trial products were administered by CSII using a MiniMed Paradigm Veo&#x02122;754 insulin pump with a Paradigm Reservoir 3.0 mL and a Quick&#x02010;set infusion set with a 6&#x02010;mm cannula and a 23&#x02010;inch tube (Medtronic MiniMed, Northridge, California). The cannula was inserted subcutaneously in the region of the lower abdominal wall above the inguinal area. One infusion site was used throughout the first dosing visit, while another infusion site within the same region was used throughout the second dosing visit.</p><p id="dom12803-para-0014">At the dosing visits, participants came to the clinical site at 5:00 <sc>pm</sc>, after fasting since 10:00 <sc>am</sc> (water and &#x02264;20 g of rapidly absorbable carbohydrate to prevent hypoglycaemia were allowed). Participants using multiple daily insulin injections were not allowed to use insulin degludec &#x02264;72 hours pre&#x02010;dose and insulin detemir or insulin glargine &#x02264;48 hours pre&#x02010;dose (NPH insulin could be used instead). The last injection of NPH insulin or other intermediate&#x02010;acting insulin had to occur at least 22 hours pre&#x02010;dose, the last injection or bolus administration by CSII of insulin aspart had to occur at least 12 hours pre&#x02010;dose (RHI could be used instead) and the last injection of RHI or other short&#x02010;acting insulin (other than insulin aspart) had to occur at least 6 hours pre&#x02010;dose. Participants using CSII had to discontinue the basal rate at least 3 hours pre&#x02010;dose (or at least 8 hours pre&#x02010;dose if using insulin aspart).</p><p id="dom12803-para-0015">Participants were excluded from the dosing visit if they had experienced hypoglycaemia (plasma glucose &#x02264; 3.9 mmol/L) &#x02264;24 hours pre&#x02010;dose.</p><p id="dom12803-para-0016">At 7:00 <sc>pm</sc>, participants received faster aspart or insulin aspart at an initial priming dose of 0.08 U/kg, followed by a basal rate of 0.02 U/kg/h for 27 hours, on top of which a single bolus dose of 0.15 U/kg was given after 13 hours (i.e. after 22 hours of fasting; Figure S1, Appendix S1). The duration of bolus infusion administered by the insulin pump was 3.7 to 8.3 minutes, depending on absolute dose.</p><p id="dom12803-para-0017">A euglycaemic clamp procedure was initiated 30 minutes before the priming dose using ClampArt (Profil). Participants received a variable intravenous infusion of RHI (15 IU Actrapid [100 IU/mL; Novo Nordisk] in 49 mL saline and 1 mL of the participant's blood) or 20% glucose to achieve the blood glucose clamp target level of 5.5 mmol/L. The intravenous RHI infusion (if any) was only allowed until 8 hours before the bolus dose of trial product. The clamp continued for 14 hours after the bolus dose. The quality of the conducted clamps is shown in Figure S2, Appendix S1.<xref rid="dom12803-bib-0014" ref-type="ref">14</xref>
</p><p id="dom12803-para-0018">Blood samples for pharmacokinetic assessment were drawn frequently at prespecified time points from before the insulin priming dose until the end of the CSII (27 hours after the priming dose).</p></sec><sec id="dom12803-sec-0010"><label>2.4</label><title>Assessments and endpoints</title><p id="dom12803-para-0019">Free serum insulin aspart concentrations (polyethylene glycol&#x02010;precipitated) were measured using a validated insulin aspart specific enzyme&#x02010;linked immunosorbent assay. The intravenous glucose infusion rate (GIR) needed to keep blood glucose at the clamp target level was recorded every minute during the glucose clamp. Safety assessments included adverse events, local tolerability at the infusion site, hypoglycaemic episodes (defined as &#x0201c;confirmed&#x0201d; when they were either &#x0201c;severe&#x0201d; as according to the American Diabetes Association, i.e. requiring third party assistance,<xref rid="dom12803-bib-0015" ref-type="ref">15</xref> or verified by a plasma glucose level of &#x0003c;3.1 mmol/L), laboratory safety variables, physical examination, vital signs and ECG.</p><p id="dom12803-para-0020">Endpoints to evaluate onset of exposure and glucose&#x02010;lowering effect included: time to early 50% of maximum insulin concentration (t<sub>Early 50% Cmax</sub>); time to maximum insulin concentration (t<sub>max</sub>); time to early 50% of maximum GIR (t<sub>Early 50% GIRmax</sub>); and time to maximum GIR (tGIR<sub>max</sub>). Endpoints to evaluate early exposure and glucose&#x02010;lowering effect included the early partial areas under the curve (AUCs) for serum insulin aspart [AUC<sub>IAsp,0&#x02010;15min</sub>, AUC<sub>IAsp,0&#x02010;30min</sub> (primary endpoint), AUC<sub>IAsp,0&#x02010;1h</sub>, AUC<sub>IAsp,0&#x02010;1.5h</sub>, and AUC<sub>IAsp,0&#x02010;2h</sub>] and the early partial AUCs for GIR [AUC<sub>GIR,0&#x02010;30min</sub>, AUC<sub>GIR,0&#x02010;1h</sub>, AUC<sub>GIR,0&#x02010;1.5h</sub>, and AUC<sub>GIR,0&#x02010;2h</sub>]. Endpoints to evaluate offset of exposure and glucose&#x02010;lowering effect were time to late 50% of maximum insulin concentration (t<sub>Late 50% Cmax</sub>) and time to late 50% of maximum GIR (t<sub>Late 50% GIRmax</sub>; both derived <italic>post hoc</italic>). Endpoints to evaluate overall exposure and glucose&#x02010;lowering effect were total insulin exposure (AUC<sub>IAsp,0&#x02010;t</sub>), maximum insulin concentration (C<sub>max</sub>), total glucose&#x02010;lowering effect (AUC<sub>GIR,0&#x02010;t</sub>), and maximum GIR (GIR<sub>max</sub>). All endpoints were corrected for the basal insulin infusion in order to obtain values related solely to the bolus insulin dose. AUC<sub>insulin aspart,0&#x02010;t</sub> and AUC<sub>GIR,0&#x02010;t</sub> were derived from time zero until the first non&#x02010;positive baseline infusion corrected insulin aspart concentration or smoothed GIR, respectively, in the terminal part of the profile (however, no longer than 12 hours). Endpoints were derived from the raw profiles except for t<sub>Early 50% GIRmax</sub>, GIR<sub>max</sub>, tGIR<sub>max</sub> and t<sub>Late 50% GIRmax</sub>, which were derived from LOESS smoothed GIR profiles (using a smoothing factor of 0.1) to ensure robust calculation.</p></sec><sec id="dom12803-sec-0011"><label>2.5</label><title>Statistical analysis</title><p id="dom12803-para-0021">Statistical analyses of pharmacokinetic and pharmacodynamic endpoints were conducted using <sc>sas</sc> version 9.3 (SAS Institute, Cary, North Carolina) based on all randomized participants receiving at least 1 dose of trial product. Safety endpoints were summarized using descriptive statistics based on all participants receiving at least 1 dose of trial product.</p><p id="dom12803-para-0022">To ensure sufficient power to evaluate treatment differences, both for pharmacokinetic and pharmacodynamic endpoints, the sample size calculation was performed not only for the primary pharmacokinetic endpoint, AUC<sub>IAsp,0&#x02010;30min</sub>, but also for the secondary pharmacodynamic endpoint, AUC<sub>GIR,0&#x02010;1h</sub>. The number of completers required was 31 in order to obtain 80% power for detecting a geometric mean treatment ratio of 1.5 for AUC<sub>IAsp,0&#x02010;30min</sub>. This was based on an assumed within&#x02010;subject standard deviation (on log&#x02010;scale) of 0.54 (derived from a previous trial with faster aspart<xref rid="dom12803-bib-0011" ref-type="ref">11</xref> and taking into account that the baseline correction of AUCs in this trial contributed further to the variation) and a significance level of 5%; however, in order to also obtain sufficient power for pharmacodynamic endpoints, the number of completers required in this trial was set to 44 participants. This yielded 80% power for detecting a geometric mean treatment ratio of 1.3 for AUC<sub>GIR,0&#x02010;1h</sub>, based on an assumed within&#x02010;subject standard deviation (on log&#x02010;scale) of 0.3 and a significance level of 5%.<xref rid="dom12803-bib-0011" ref-type="ref">11</xref>
</p><p id="dom12803-para-0023">Pharmacokinetic and pharmacodynamic endpoints were analysed by means of a linear mixed model, with treatment and period as fixed effects and participant as random effect. For the AUCs, a multiplicative linear mixed model was used if all individual AUC values were strictly positive. If there were non&#x02010;positive individual AUC values, an additive model was used. For C<sub>max</sub> and GIR<sub>max</sub>, a multiplicative model was used, while for t<sub>Early 50% Cmax</sub>, t<sub>max</sub>, t<sub>Late 50% Cmax</sub>, t<sub>Early 50% GIRmax</sub>, tGIR<sub>max</sub> and t<sub>Late 50% GIRmax</sub>, an additive model was used. For endpoints analysed using an additive model, treatment ratios and 95% confidence intervals (CIs) were calculated using Fieller's method.<xref rid="dom12803-bib-0016" ref-type="ref">16</xref>
</p></sec></sec><sec id="dom12803-sec-0012"><label>3</label><title>RESULTS</title><sec id="dom12803-sec-0013"><label>3.1</label><title>Participant disposition and baseline characteristics</title><p id="dom12803-para-0024">A total of 58 individuals were screened, 48 were randomized and treated with trial product, and 46 completed the trial. Two participants were withdrawn (1 as a result of an adverse event of vomiting after insulin aspart treatment and 1 because of a technical problem with a catheter). Participant disposition is presented in Figure S3, Appendix S1.</p><p id="dom12803-para-0025">The mean (&#x000b1; standard deviation [s.d.]) age of the participants was 46.3 (&#x000b1;8.6) years. The majority of participants were men (66.7%), and all participants were white. The mean body weight was 76.5 (&#x000b1;11.8) kg, mean BMI was 24.5 (&#x000b1;2.3) kg/m<sup>2</sup>, mean duration of diabetes was 24.1 (&#x000b1;12.2) years, and mean HbA<sub>1c</sub> at baseline was 7.4% (&#x000b1;0.6%). At entry into the study, 34 participants were receiving multiple daily injection therapy and 14 participants were using CSII.</p></sec><sec id="dom12803-sec-0014"><label>3.2</label><title>Onset of exposure and glucose&#x02010;lowering effect</title><p id="dom12803-para-0026">After a bolus dose administered by CSII, both the serum insulin concentration&#x02013;time profile (Figure <xref rid="dom12803-fig-0001" ref-type="fig">1</xref>) and the glucose&#x02010;lowering effect profile (Figure <xref rid="dom12803-fig-0002" ref-type="fig">2</xref>) were shifted to the left for faster aspart vs insulin aspart. With faster aspart, t<sub>Early 50% Cmax</sub> was 11.8 minutes earlier, and t<sub>max</sub> was 25.7 minutes earlier, compared with insulin aspart (Table <xref rid="dom12803-tbl-0001" ref-type="table-wrap">1</xref> and Figure <xref rid="dom12803-fig-0001" ref-type="fig">1</xref>). Likewise, t<sub>Early 50% GIRmax</sub> was 11.1 minutes earlier, and tGIR<sub>max</sub> was 18.7 minutes earlier for faster aspart vs insulin aspart (Table <xref rid="dom12803-tbl-0002" ref-type="table-wrap">2</xref>).</p><fig fig-type="Figure" xml:lang="en" id="dom12803-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mean serum <styled-content style="fixed-case">insulin aspart</styled-content> concentration after a bolus dose of 0.15 U/kg faster aspart or <styled-content style="fixed-case">insulin aspart</styled-content> administered by <styled-content style="fixed-case">CSII</styled-content>. Variability bands show the s.e.m. The full blue/grey arrows indicate that the estimated onset and offset of exposure occurred earlier for faster aspart vs <styled-content style="fixed-case">insulin aspart</styled-content> as reflected by the endpoints time to 50% of maximum <styled-content style="fixed-case">insulin aspart</styled-content> concentration in the early part of the pharmacokinetic profile (t<sub>Early 50%</sub>
<styled-content style="fixed-case"><sub>Cmax</sub></styled-content>; estimated difference [95% <styled-content style="fixed-case">CI</styled-content>] faster aspart &#x02013; <styled-content style="fixed-case">insulin aspart</styled-content> &#x02212;11.8 minutes [&#x02212;14.4; &#x02212;9.2]; <styled-content style="italic-in-any-context">
P
</styled-content> &#x0003c; .001) and time to 50% of maximum <styled-content style="fixed-case">insulin aspart</styled-content> concentration in the late part of the pharmacokinetic profile (t<sub>Late 50%</sub>
<styled-content style="fixed-case"><sub>Cmax</sub></styled-content>; &#x02212;35.4 minutes [&#x02212;47.0; &#x02212;23.8]; <styled-content style="italic-in-any-context">
P
</styled-content> &#x0003c; .001). Moreover, as indicated by the dashed arrow, a left shift of the time of maximum <styled-content style="fixed-case">insulin aspart</styled-content> concentration was also observed for faster aspart vs <styled-content style="fixed-case">insulin aspart</styled-content> (t<sub>max</sub>; &#x02212;25.7 minutes [&#x02212;34.3; &#x02212;17.1]; <styled-content style="italic-in-any-context">
P
</styled-content> &#x0003c; .001). For graphical reasons, there are some discrepancies between the length of the arrows and the actual estimated mean treatment differences. This is attributable to the fact that the estimated mean treatment differences are derived from all participants&#x02019; individual treatment differences, while the mean serum <styled-content style="fixed-case">insulin aspart</styled-content> concentration profiles are derived as the mean of all individual serum <styled-content style="fixed-case">insulin aspart</styled-content> concentrations at each time point. Faster aspart, n = 44; <styled-content style="fixed-case">insulin aspart</styled-content>, n = 46.</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-19-208-g001"/></fig><fig fig-type="Figure" xml:lang="en" id="dom12803-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mean glucose&#x02010;lowering effect after a bolus dose of 0.15 U/kg faster aspart or <styled-content style="fixed-case">insulin aspart</styled-content> administered by <styled-content style="fixed-case">CSII</styled-content>. Variability bands show the s.e.m. Faster aspart, n = 44; <styled-content style="fixed-case">insulin aspart</styled-content>, n = 46.</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-19-208-g003"/></fig><table-wrap id="dom12803-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Onset, offset and overall exposure for faster aspart (n = 44) and <styled-content style="fixed-case">insulin aspart</styled-content> (n = 46) after a bolus dose of 0.15 U/kg administered by <styled-content style="fixed-case">CSII</styled-content>
</p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="(" span="1"/><col width="1*" align="char" char="(" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th id="dom12803-ent-0001" align="left" valign="bottom" rowspan="1" colspan="1"/><th id="dom12803-ent-0002" align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Faster aspart</bold>
<xref ref-type="fn" rid="dom12803-note-0003">
<sup>1</sup>
</xref>
</th><th id="dom12803-ent-0003" align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Insulin aspart</bold>
<xref ref-type="fn" rid="dom12803-note-0003">
<sup>1</sup>
</xref>
</th><th id="dom12803-ent-0004" align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Treatment ratio</bold>
<xref ref-type="fn" rid="dom12803-note-0004">
<sup>2</sup>
</xref>
<bold>(95% CI)</bold>
</th><th id="dom12803-ent-0005" align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Treatment difference</bold>
<xref ref-type="fn" rid="dom12803-note-0005">
<sup>3</sup>
</xref>
<bold>(95% CI)</bold>
</th><th id="dom12803-ent-0006" align="center" valign="bottom" rowspan="1" colspan="1">
<italic><bold>P</bold></italic>
</th></tr></thead><tbody valign="top"><tr><td colspan="6" id="dom12803-ent-0007" align="left" valign="top" rowspan="1">
<bold>Onset of exposure, min</bold>
</td></tr><tr><td style="padding-left:10%" id="dom12803-ent-0008" align="left" valign="top" rowspan="1" colspan="1">t<sub>Early 50% Cmax</sub>
</td><td char="." id="dom12803-ent-0009" align="char" valign="top" rowspan="1" colspan="1">20.7</td><td char="." id="dom12803-ent-0010" align="char" valign="top" rowspan="1" colspan="1">32.5</td><td char="(" id="dom12803-ent-0011" align="char" valign="top" rowspan="1" colspan="1">0.64 (0.57; 0.71)</td><td char="(" id="dom12803-ent-0012" align="char" valign="top" rowspan="1" colspan="1">&#x02212;11.8 (&#x02212;14.4; &#x02212;9.2)</td><td char="." id="dom12803-ent-0013" align="char" valign="top" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td style="padding-left:10%" id="dom12803-ent-0014" align="left" valign="top" rowspan="1" colspan="1">t<sub>max</sub>
</td><td char="." id="dom12803-ent-0015" align="char" valign="top" rowspan="1" colspan="1">56.6</td><td char="." id="dom12803-ent-0016" align="char" valign="top" rowspan="1" colspan="1">82.3</td><td char="(" id="dom12803-ent-0017" align="char" valign="top" rowspan="1" colspan="1">0.69 (0.60; 0.78)</td><td char="(" id="dom12803-ent-0018" align="char" valign="top" rowspan="1" colspan="1">&#x02212;25.7 (&#x02212;34.3; &#x02212;17.1)</td><td char="." id="dom12803-ent-0019" align="char" valign="top" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td colspan="6" char="." id="dom12803-ent-0020" align="left" valign="top" rowspan="1">
<bold>Offset of exposure, min</bold>
</td></tr><tr><td style="padding-left:10%" id="dom12803-ent-0021" align="left" valign="top" rowspan="1" colspan="1">t<sub>Late 50% Cmax</sub>
</td><td char="." id="dom12803-ent-0022" align="char" valign="top" rowspan="1" colspan="1">137.4</td><td char="." id="dom12803-ent-0023" align="char" valign="top" rowspan="1" colspan="1">172.9</td><td char="(" id="dom12803-ent-0024" align="char" valign="top" rowspan="1" colspan="1">0.80 (0.73; 0.86)</td><td char="(" id="dom12803-ent-0025" align="char" valign="top" rowspan="1" colspan="1">&#x02212;35.4 (&#x02212;47.0; &#x02212;23.8)</td><td char="." id="dom12803-ent-0026" align="char" valign="top" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td colspan="6" char="." id="dom12803-ent-0027" align="left" valign="top" rowspan="1">
<bold>Overall exposure</bold>
</td></tr><tr><td style="padding-left:10%" id="dom12803-ent-0028" align="left" valign="top" rowspan="1" colspan="1">AUC<sub>IAsp,0&#x02010;t</sub>, pmol*h/L</td><td char="." id="dom12803-ent-0029" align="char" valign="top" rowspan="1" colspan="1">606.2</td><td char="." id="dom12803-ent-0030" align="char" valign="top" rowspan="1" colspan="1">622.8</td><td char="(" id="dom12803-ent-0031" align="char" valign="top" rowspan="1" colspan="1">0.97 (0.90; 1.05)</td><td char="(" id="dom12803-ent-0032" align="char" valign="top" rowspan="1" colspan="1">NA</td><td char="." id="dom12803-ent-0033" align="char" valign="top" rowspan="1" colspan="1">.477</td></tr><tr><td style="padding-left:10%" id="dom12803-ent-0034" align="left" valign="top" rowspan="1" colspan="1">C<sub>max</sub>, pmol/L</td><td char="." id="dom12803-ent-0035" align="char" valign="top" rowspan="1" colspan="1">278.9</td><td char="." id="dom12803-ent-0036" align="char" valign="top" rowspan="1" colspan="1">252.1</td><td char="(" id="dom12803-ent-0037" align="char" valign="top" rowspan="1" colspan="1">1.11 (1.03; 1.19)</td><td char="(" id="dom12803-ent-0038" align="char" valign="top" rowspan="1" colspan="1">NA</td><td char="." id="dom12803-ent-0039" align="char" valign="top" rowspan="1" colspan="1">.010</td></tr></tbody></table><table-wrap-foot><fn id="dom12803-note-0002"><p>
<styled-content style="fixed-case">NA</styled-content>, not applicable; t, time of first non&#x02010;positive baseline infusion corrected <styled-content style="fixed-case">insulin aspart</styled-content> concentration in the terminal part of the profile (however, no longer than 12 hours).</p></fn><fn id="dom12803-note-0003"><label><sup>1</sup></label><p>Data are least squares means.</p></fn><fn id="dom12803-note-0004"><label><sup>2</sup></label><p>Faster aspart/<styled-content style="fixed-case">insulin aspart</styled-content> (for onset and offset of exposure endpoints, the treatment ratio was calculated using Fieller's method).</p></fn><fn id="dom12803-note-0005"><label><sup>3</sup></label><p>Faster aspart &#x02013; <styled-content style="fixed-case">insulin aspart</styled-content>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="dom12803-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Onset, offset and overall glucose&#x02010;lowering effect for faster aspart (n = 44) and <styled-content style="fixed-case">insulin aspart</styled-content> (n = 45) after a bolus dose of 0.15 U/kg administered by <styled-content style="fixed-case">CSII</styled-content>
</p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="(" span="1"/><col width="1*" align="char" char="(" span="1"/><col width="1*" align="char" char="." span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th id="dom12803-ent-0040" align="left" valign="bottom" rowspan="1" colspan="1"/><th id="dom12803-ent-0041" align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Faster aspart</bold>
<xref ref-type="fn" rid="dom12803-note-0008">
<sup>1</sup>
</xref>
</th><th id="dom12803-ent-0042" align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Insulin aspart</bold>
<xref ref-type="fn" rid="dom12803-note-0008">
<sup>1</sup>
</xref>
</th><th id="dom12803-ent-0043" align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Treatment ratio</bold>
<xref ref-type="fn" rid="dom12803-note-0009">
<sup>2</sup>
</xref>
<bold>(95% CI)</bold>
</th><th id="dom12803-ent-0044" align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Treatment difference</bold>
<xref ref-type="fn" rid="dom12803-note-0010">
<sup>3</sup>
</xref>
<bold>(95% CI)</bold>
</th><th id="dom12803-ent-0045" align="center" valign="bottom" rowspan="1" colspan="1">
<italic><bold>P</bold></italic>
</th></tr></thead><tbody valign="top"><tr><td colspan="6" id="dom12803-ent-0046" align="left" valign="top" rowspan="1">
<bold>Onset of glucose&#x02010;lowering effect</bold>, <bold>min</bold>
</td></tr><tr><td style="padding-left:10%" id="dom12803-ent-0047" align="left" valign="top" rowspan="1" colspan="1">t<sub>Early 50% GIRmax</sub>
</td><td char="." id="dom12803-ent-0048" align="char" valign="top" rowspan="1" colspan="1">41.1</td><td char="." id="dom12803-ent-0049" align="char" valign="top" rowspan="1" colspan="1">52.3</td><td char="(" id="dom12803-ent-0050" align="char" valign="top" rowspan="1" colspan="1">0.79 (0.72; 0.86)</td><td char="(" id="dom12803-ent-0051" align="char" valign="top" rowspan="1" colspan="1">&#x02212;11.1 (&#x02212;15.4; &#x02212;6.9)</td><td char="." id="dom12803-ent-0052" align="char" valign="top" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td style="padding-left:10%" id="dom12803-ent-0053" align="left" valign="top" rowspan="1" colspan="1">tGIR<sub>max</sub>
</td><td char="." id="dom12803-ent-0054" align="char" valign="top" rowspan="1" colspan="1">111.9</td><td char="." id="dom12803-ent-0055" align="char" valign="top" rowspan="1" colspan="1">130.6</td><td char="(" id="dom12803-ent-0056" align="char" valign="top" rowspan="1" colspan="1">0.86 (0.75; 0.97)</td><td char="(" id="dom12803-ent-0057" align="char" valign="top" rowspan="1" colspan="1">&#x02212;18.7 (&#x02212;34.4; &#x02212;2.9)</td><td char="." id="dom12803-ent-0058" align="char" valign="top" rowspan="1" colspan="1">.021</td></tr><tr><td colspan="6" char="." id="dom12803-ent-0059" align="left" valign="top" rowspan="1">
<bold>Offset of glucose&#x02010;lowering effect, min</bold>
</td></tr><tr><td style="padding-left:10%" id="dom12803-ent-0060" align="left" valign="top" rowspan="1" colspan="1">t<sub>Late 50% GIRmax</sub>
</td><td char="." id="dom12803-ent-0061" align="char" valign="top" rowspan="1" colspan="1">214.7</td><td char="." id="dom12803-ent-0062" align="char" valign="top" rowspan="1" colspan="1">238.7</td><td char="(" id="dom12803-ent-0063" align="char" valign="top" rowspan="1" colspan="1">0.90 (0.84; 0.96)</td><td char="(" id="dom12803-ent-0064" align="char" valign="top" rowspan="1" colspan="1">&#x02212;24.0 (&#x02212;38.9; &#x02212;9.1)</td><td char="." id="dom12803-ent-0065" align="char" valign="top" rowspan="1" colspan="1">.002</td></tr><tr><td colspan="6" char="." id="dom12803-ent-0066" align="left" valign="top" rowspan="1">
<bold>Overall glucose&#x02010;lowering effect</bold>
</td></tr><tr><td style="padding-left:10%" id="dom12803-ent-0067" align="left" valign="top" rowspan="1" colspan="1">AUC<sub>GIR,0&#x02010;t</sub>, mg/kg</td><td char="." id="dom12803-ent-0068" align="char" valign="top" rowspan="1" colspan="1">1341.5</td><td char="." id="dom12803-ent-0069" align="char" valign="top" rowspan="1" colspan="1">1295.7</td><td char="(" id="dom12803-ent-0070" align="char" valign="top" rowspan="1" colspan="1">1.04 (0.95; 1.13)</td><td char="(" id="dom12803-ent-0071" align="char" valign="top" rowspan="1" colspan="1">NA</td><td char="." id="dom12803-ent-0072" align="char" valign="top" rowspan="1" colspan="1">.427</td></tr><tr><td style="padding-left:10%" id="dom12803-ent-0073" align="left" valign="top" rowspan="1" colspan="1">GIR<sub>max</sub>, mg/kg/min</td><td char="." id="dom12803-ent-0074" align="char" valign="top" rowspan="1" colspan="1">7.1</td><td char="." id="dom12803-ent-0075" align="char" valign="top" rowspan="1" colspan="1">6.8</td><td char="(" id="dom12803-ent-0076" align="char" valign="top" rowspan="1" colspan="1">1.04 (0.94; 1.14)</td><td char="(" id="dom12803-ent-0077" align="char" valign="top" rowspan="1" colspan="1">NA</td><td char="." id="dom12803-ent-0078" align="char" valign="top" rowspan="1" colspan="1">.439</td></tr></tbody></table><table-wrap-foot><fn id="dom12803-note-0006"><p>
<styled-content style="fixed-case">NA</styled-content>, not applicable; t, time of first non&#x02010;positive baseline infusion corrected <styled-content style="fixed-case">GIR</styled-content> in the terminal part of the smoothed <styled-content style="fixed-case">GIR</styled-content> profile (however, no longer than 12 hours).</p></fn><fn id="dom12803-note-0008"><label><sup>1</sup></label><p>Data are least squares means.</p></fn><fn id="dom12803-note-0009"><label><sup>2</sup></label><p>Faster aspart/<styled-content style="fixed-case">insulin aspart</styled-content> (for onset and offset of glucose&#x02010;lowering effect endpoints, the treatment ratio was calculated using Fieller's method).</p></fn><fn id="dom12803-note-0010"><label><sup>3</sup></label><p>Faster aspart &#x02013; <styled-content style="fixed-case">insulin aspart</styled-content>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dom12803-sec-0015"><label>3.3</label><title>Early exposure and glucose&#x02010;lowering effect</title><p id="dom12803-para-0027">Early insulin exposure and glucose&#x02010;lowering effect were both greater for faster aspart than for insulin aspart, as shown by the significantly greater partial AUCs and GIR AUCs for faster aspart vs insulin aspart within the first 2 hours of the bolus insulin dose (Figure <xref rid="dom12803-fig-0003" ref-type="fig">3</xref>). Early exposure during the first 15 minutes after the bolus dose (AUC<sub>IAsp,0&#x02010;15min</sub>) was significantly greater for faster aspart vs insulin aspart (least squares means of 12.5 and 1.8 pmol*h/L, respectively; <italic>P</italic> &#x0003c; .001). Within the first 30 minutes after the bolus dose, a ~3&#x02010;fold higher insulin exposure (AUC<sub>IAsp,0&#x02010;30min</sub>; primary endpoint) and a ~2&#x02010;fold greater glucose&#x02010;lowering effect (AUC<sub>GIR,0&#x02010;30min</sub>) were seen with faster aspart than with insulin aspart (Figure <xref rid="dom12803-fig-0003" ref-type="fig">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="dom12803-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Early exposure (A) and early glucose&#x02010;lowering effect (B) for faster aspart vs <styled-content style="fixed-case">insulin aspart</styled-content> after a bolus dose of 0.15 U/kg administered by <styled-content style="fixed-case">CSII</styled-content>. n = 44 for faster aspart and n = 45 (<styled-content style="fixed-case">AUC<sub>GIR</sub></styled-content>
<sub>,0&#x02010;1.5h</sub> and <styled-content style="fixed-case">AUC<sub>GIR</sub></styled-content>
<sub>,0&#x02010;2h</sub>) or 46 (all other endpoints) for <styled-content style="fixed-case">insulin aspart</styled-content>. The treatment ratio for <styled-content style="fixed-case">AUC<sub>GIR</sub></styled-content>
<sub>,0&#x02010;30min</sub> and <styled-content style="fixed-case">AUC<sub>GIR</sub></styled-content>
<sub>,0&#x02010;1h</sub> was calculated using Fieller's method. <styled-content style="fixed-case">LS</styled-content>, least squares.</p></caption><graphic id="nlm-graphic-5" xlink:href="DOM-19-208-g002"/></fig></sec><sec id="dom12803-sec-0016"><label>3.4</label><title>Offset of exposure and glucose&#x02010;lowering effect</title><p id="dom12803-para-0028">The offset of insulin exposure after a bolus dose administered by CSII occurred earlier for faster aspart than for insulin aspart, as shown by a 35.4 minutes earlier t<sub>Late 50% Cmax</sub> for faster aspart vs insulin aspart (Table <xref rid="dom12803-tbl-0001" ref-type="table-wrap">1</xref> and Figure <xref rid="dom12803-fig-0001" ref-type="fig">1</xref>). Likewise, the offset of glucose&#x02010;lowering effect occurred faster for faster aspart than for insulin aspart, as shown by a 24.0 minutes earlier t<sub>Late 50% GIRmax</sub> for faster aspart vs insulin aspart (Table <xref rid="dom12803-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec><sec id="dom12803-sec-0017"><label>3.5</label><title>Overall exposure and glucose&#x02010;lowering effect</title><p id="dom12803-para-0029">The total insulin exposure (AUC<sub>IAsp,0&#x02010;t</sub>) was similar for faster aspart and insulin aspart, while the C<sub>max</sub> was slightly greater for faster aspart than for insulin aspart (Table <xref rid="dom12803-tbl-0001" ref-type="table-wrap">1</xref>). The total glucose&#x02010;lowering effect (AUC<sub>GIR,0&#x02010;t</sub>) and the GIR<sub>max</sub> were both similar for faster aspart and insulin aspart (Table <xref rid="dom12803-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec><sec id="dom12803-sec-0018"><label>3.6</label><title>Safety</title><p id="dom12803-para-0030">Both faster aspart and insulin aspart were well tolerated, and no safety issues were identified during the trial. No infusion site reactions were reported when administering faster aspart or insulin aspart by CSII. No confirmed hypoglycaemic episodes occurred during the trial.</p></sec></sec><sec id="dom12803-sec-0019"><label>4</label><title>DISCUSSION</title><p id="dom12803-para-0031">The key findings of the present study, which is the first to investigate the pharmacokinetic and pharmacodynamic properties of faster aspart in a pump setting, were that in individuals with T1DM, faster aspart provided faster onset, greater early exposure and early glucose&#x02010;lowering effect and faster offset compared with insulin aspart. In addition, faster aspart was well tolerated. Faster aspart may therefore have the potential to provide improved postprandial glycaemic control over current rapid&#x02010;acting insulins in a pump setting. Indeed, in a double&#x02010;blind, randomized, crossover study in 43 individuals with T1DM using CSII for 14 days, faster aspart provided a 25% greater plasma glucose&#x02010;lowering effect during the first 2 hours of a standardized meal test compared with insulin aspart.<xref rid="dom12803-bib-0017" ref-type="ref">17</xref> Furthermore, the mean postprandial increment in interstitial glucose across all meals over 14 days, measured by blinded continuous glucose monitoring in the outpatient setting, was ~50% lower for faster aspart than for insulin aspart, both at 60 and 120 minutes post&#x02010;meal.<xref rid="dom12803-bib-0017" ref-type="ref">17</xref> Reduction of postprandial glucose excursions may play an important role in improving overall glycaemic control, especially at lower HbA<sub>1c</sub> levels as suggested by some studies.<xref rid="dom12803-bib-0018" ref-type="ref">18</xref>, <xref rid="dom12803-bib-0019" ref-type="ref">19</xref> Although a prominent contribution of postprandial glucose to HbA<sub>1c</sub> levels was not confirmed by a later randomized controlled trial,<xref rid="dom12803-bib-0020" ref-type="ref">20</xref> all studies show that postprandial glucose has some impact on HbA<sub>1c</sub>. This was also confirmed by an improvement in HbA<sub>1c</sub> of 0.15% with faster aspart compared with insulin aspart in individuals with T1DM using multiple daily injection therapy.<xref rid="dom12803-bib-0021" ref-type="ref">21</xref> It remains to be seen if further improvements can be achieved with faster aspart in a CSII setting as the current pharmacokinetic and pharmacodynamic data suggest.</p><p id="dom12803-para-0032">In healthy individuals, early endogenous insulin secretion in response to a meal induces a prompt suppression of hepatic glucose production, which appears to play a major role in controlling postprandial glucose levels. Accordingly, the concept of CSII in patients with diabetes relies on immediate action of the mealtime insulin administered. Current rapid&#x02010;acting insulin analogues have shown some improvements over RHI in terms of accelerated insulin absorption.<xref rid="dom12803-bib-0002" ref-type="ref">2</xref>, <xref rid="dom12803-bib-0003" ref-type="ref">3</xref> There is, however, still room for further improvement in mealtime insulin absorption rate.<xref rid="dom12803-bib-0022" ref-type="ref">22</xref>, <xref rid="dom12803-bib-0023" ref-type="ref">23</xref> The results of the present trial, as well as those of previous trials, suggest that faster aspart may better reproduce the physiological insulin action profile seen in response to a meal in healthy individuals.<xref rid="dom12803-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12803-bib-0024" ref-type="ref">24</xref>
</p><p id="dom12803-para-0033">Another aim when optimizing insulin for use in CSII has been to increase the rate of offset, in order to reduce the risk of late postprandial hypoglycaemia.<xref rid="dom12803-bib-0005" ref-type="ref">5</xref>, <xref rid="dom12803-bib-0009" ref-type="ref">9</xref> The duration of mealtime insulin requirement depends on several individual factors, such as food composition and rate of gastric emptying, and there is a limit to the optimum rate of offset because a very fast offset of action could imply insufficient insulin action in the late postprandial period.<xref rid="dom12803-bib-0025" ref-type="ref">25</xref> It was shown in the present study that faster aspart had a faster offset of exposure and action compared with insulin aspart. In standardized meal tests following faster aspart or insulin aspart administration by subcutaneous injection or CSII, plasma glucose for faster aspart was consistently lower than or equal to insulin aspart up to 4 to 6 hours post&#x02010;meal.<xref rid="dom12803-bib-0017" ref-type="ref">17</xref>, <xref rid="dom12803-bib-0024" ref-type="ref">24</xref> This indicates that the rate of offset is not too rapid with faster aspart. Specifically designed studies are needed to further investigate the relationship between rate of offset and the risk of late postprandial hypoglycaemia with faster aspart.</p><p id="dom12803-para-0034">When comparing the present results for faster aspart using CSII with those previously reported for subcutaneous injection, it appears that improvements in onset as well as early exposure and action with faster aspart vs insulin aspart are most pronounced in the pump setting.<xref rid="dom12803-bib-0011" ref-type="ref">11</xref> Treatment ratios of faster aspart vs insulin aspart for AUC<sub>IAsp,0&#x02010;30min</sub> and AUC<sub>GIR,0&#x02010;30min</sub> were 2.95 and 2.18 in the present study as compared with 2.05 and 1.48 after subcutaneous injection.<xref rid="dom12803-bib-0011" ref-type="ref">11</xref> It should be noted that this is a comparison between two different studies and ideally a dedicated study needs to be performed to reach firm conclusions regarding the pharmacokinetic and pharmacodynamic properties of faster aspart relative to insulin aspart after subcutaneous injection vs CSII. One of the excipients in faster aspart, niacinamide, promotes the formation of insulin aspart monomers in diluted formulations mimicking subcutaneous conditions after administration, and augments the permeation rate of insulin aspart in human dermal&#x02010;derived microvascular capillary endothelial cell monolayers.<xref rid="dom12803-bib-0026" ref-type="ref">26</xref> It may be speculated that the continuous presence of niacinamide at the infusion site in the CSII setting due to the basal infusion rate and/or the duration of the bolus infusion may further facilitate the rapid absorption of faster aspart as compared with the single injection setting where dosing occurs almost instantaneously and niacinamide might disappear relatively quickly from the injection site. Another hypothesis could be that the mode of delivery of the bolus infusion when using CSII favours a better diffusion of faster aspart in the subcutaneous tissue until reaching the capillaries. These potential mechanisms are, however, solely speculative at the moment and further investigations are needed within this area.</p><p id="dom12803-para-0035">Differences in duration of the bolus infusion between different insulin pumps have previously been shown to affect the pharmacokinetic and pharmacodynamic characteristics of mealtime insulin.<xref rid="dom12803-bib-0027" ref-type="ref">27</xref> In the present study, the same insulin pump with the same bolus infusion mode was used for the two treatments in a crossover design. Consequently, the duration of bolus infusion was similar for faster aspart and insulin aspart within each participant. Importantly, in the study by Bode et al.,<xref rid="dom12803-bib-0017" ref-type="ref">17</xref> reduced postprandial glucose increment was observed with faster aspart compared with insulin aspart across several models of insulin pumps with different speed of bolus delivery.</p><p id="dom12803-para-0036">As a result of the bolus being administered on top of a basal insulin infusion, it was not possible to assess onset of appearance and onset of action in any meaningful way using recognized methodology, which is a limitation of the present study.<xref rid="dom12803-bib-0028" ref-type="ref">28</xref> Furthermore, we showed a minor but nevertheless significant difference in C<sub>max</sub> between faster aspart and insulin aspart, which has some impact on the interpretation of t<sub>Early 50% Cmax</sub> and t<sub>Late 50% Cmax</sub>
<xref rid="dom12803-bib-0028" ref-type="ref">28</xref>; however, as C<sub>max</sub> was highest for faster aspart, it would be expected that t<sub>Early 50% Cmax</sub> and t<sub>Late 50% Cmax</sub> would have been even more in favour of faster aspart if C<sub>max</sub> had been similar between treatments. Furthermore, GIR<sub>max</sub> was similar between treatments, so the interpretation of the pharmacodynamic endpoints t<sub>Early 50% GIRmax</sub> and t<sub>Late 50% GIRmax</sub>, which were also in favour of faster aspart, is straightforward.</p><p id="dom12803-para-0037">A strength of the present study is that both pharmacokinetic and pharmacodynamic measures were obtained after a bolus insulin dose on top of a basal infusion, thus resembling a clinically relevant dosing scheme during CSII. Furthermore, the study included individuals with T1DM, which is considered the optimum population in glucose clamp studies, as this allows comparison of exogenous insulins with respect to glucose&#x02010;lowering effect without interference from endogenous insulin.<xref rid="dom12803-bib-0029" ref-type="ref">29</xref> Nevertheless, the strictly controlled conditions of the glucose clamp method, eg, the long fasting period and the wash&#x02010;out of current insulin, differ from clinical practice and may imply certain challenges in translating to clinical outcomes.</p><p id="dom12803-para-0038">In conclusion, in people with T1DM using CSII, faster aspart provides faster onset and greater early exposure and glucose&#x02010;lowering effect, as well as faster offset compared with insulin aspart, thereby better mimicking the endogenous prandial insulin secretion and action. Accordingly, faster aspart has been shown to provide improvements in postprandial glucose control over insulin aspart in individuals using CSII. Faster aspart used in an insulin pump setting may represent an advancement in insulin therapy towards optimum postprandial glucose control in patients with diabetes and may also have potential in advanced pumps and closed&#x02010;loop systems.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12803-supitem-0001"><caption><p>
<bold>Appendix S1.</bold> Experimental design of each dosing visit, glucose clamp quality and participant disposition.</p></caption><media xlink:href="DOM-19-208-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12803-sec-0020"><title>ACKNOWLEDGMENTS</title><p id="dom12803-para-0039">The authors would like to thank Henrik Jarlov, MD, and Marek Demissie, MD, Novo Nordisk, for their review and input to the manuscript and Carsten Roepstorff, PhD, CR Pharma Consult, Copenhagen, Denmark for providing medical writing support, which was funded by Novo Nordisk.</p><sec id="dom12803-sec-0021"><title>Conflict of interest</title><p id="dom12803-para-0040">T. H.&#x02019;s institution has received research grants from Adocia, AstraZeneca, Becton Dickinson, Biocon, Boehringer Ingelheim, Dance Biopharm, Eli Lilly, Gr&#x000fc;nenthal, Gulf Pharmaceutical Industries, Johnson &#x00026; Johnson, Marvel, MedImmune, Medtronic, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi, Senseonics and Zealand Pharma. In addition, T. H. is a member of advisory boards for Novo Nordisk and has received speakers' honoraria and travel grants from Eli Lilly, Mylan and Novo Nordisk. E. Z. has received travel grants from Novo Nordisk and Dance Biopharm and speakers&#x02019; honoraria from Novo Nordisk and Roche Diabetes Care. T. R. and H. H. are employees and shareholders of Novo Nordisk. L. N. has no conflict of interest to declare.</p></sec><sec id="dom12803-sec-0022"><title>Author contributions</title><p id="dom12803-para-0041">T. H. contributed to the study design, conduct/data collection, analysis and writing of the manuscript. E. Z. contributed to the study design and writing of the manuscript. L. N. contributed to the study conduct/data collection and writing of the manuscript. T. R. contributed to the data analysis and writing of the manuscript. H. H. contributed to the study design and writing of the manuscript.</p></sec></ack><ref-list content-type="cited-references" id="dom12803-bibl-0001"><title>REFERENCES</title><ref id="dom12803-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12803-cit-0001">
<string-name>
<surname>Woerle</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Neumann</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zschau</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2007</year>;<volume>77</volume>:<fpage>280</fpage>&#x02010;<lpage>285</lpage>.<pub-id pub-id-type="pmid">17240473</pub-id></mixed-citation></ref><ref id="dom12803-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12803-cit-0002">
<string-name>
<surname>Home</surname>
<given-names>PD</given-names>
</string-name>. <article-title>The pharmacokinetics and pharmacodynamics of rapid&#x02010;acting insulin analogues and their clinical consequences</article-title>. <source>Diabetes Obes Metab</source>. <year>2012</year>;<volume>14</volume>:<fpage>780</fpage>&#x02010;<lpage>788</lpage>.<pub-id pub-id-type="pmid">22321739</pub-id></mixed-citation></ref><ref id="dom12803-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12803-cit-0003">
<string-name>
<surname>Hermansen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bohl</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schioldan</surname>
<given-names>AG</given-names>
</string-name>. <article-title>Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience</article-title>. <source>Drugs</source>. <year>2016</year>;<volume>76</volume>:<fpage>41</fpage>&#x02010;<lpage>74</lpage>.<pub-id pub-id-type="pmid">26607485</pub-id></mixed-citation></ref><ref id="dom12803-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12803-cit-0004">
<string-name>
<surname>Kalra</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Ultra&#x02010;fast acting insulin analogues</article-title>. <source>Recent Pat Endocr Metab Immune Drug Discov</source>. <year>2014</year>;<volume>8</volume>:<fpage>117</fpage>&#x02010;<lpage>123</lpage>.<pub-id pub-id-type="pmid">25022572</pub-id></mixed-citation></ref><ref id="dom12803-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12803-cit-0005">
<string-name>
<surname>Heinemann</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Muchmore</surname>
<given-names>DB</given-names>
</string-name>. <article-title>Ultrafast&#x02010;acting insulins: state of the art</article-title>. <source>J Diabetes Sci Technol</source>. <year>2012</year>;<volume>6</volume>:<fpage>728</fpage>&#x02010;<lpage>742</lpage>.<pub-id pub-id-type="pmid">22920797</pub-id></mixed-citation></ref><ref id="dom12803-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12803-cit-0006">
<string-name>
<surname>Pozzilli</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Battelino</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Danne</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hovorka</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jarosz&#x02010;Chobot</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Renard</surname>
<given-names>E</given-names>
</string-name>. <article-title>Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2016</year>;<volume>32</volume>:<fpage>21</fpage>&#x02010;<lpage>39</lpage>.<pub-id pub-id-type="pmid">25865292</pub-id></mixed-citation></ref><ref id="dom12803-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12803-cit-0007">
<string-name>
<surname>Thabit</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hovorka</surname>
<given-names>R</given-names>
</string-name>. <article-title>Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons</article-title>. <source>Expert Opin Drug Deliv</source>. <year>2016</year>;<volume>13</volume>:<fpage>389</fpage>&#x02010;<lpage>400</lpage>.<pub-id pub-id-type="pmid">26618219</pub-id></mixed-citation></ref><ref id="dom12803-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12803-cit-0008">
<string-name>
<surname>Yeh</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Maruthur</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta&#x02010;analysis</article-title>. <source>Ann Intern Med</source>. <year>2012</year>;<volume>157</volume>:<fpage>336</fpage>&#x02010;<lpage>347</lpage>.<pub-id pub-id-type="pmid">22777524</pub-id></mixed-citation></ref><ref id="dom12803-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12803-cit-0009">
<string-name>
<surname>Cengiz</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Van Name</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tamborlane</surname>
<given-names>WV</given-names>
</string-name>. <article-title>Moving toward the ideal insulin for insulin pumps</article-title>. <source>Expert Rev Med Devices</source>. <year>2016</year>;<volume>13</volume>:<fpage>57</fpage>&#x02010;<lpage>69</lpage>.<pub-id pub-id-type="pmid">26560137</pub-id></mixed-citation></ref><ref id="dom12803-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="dom12803-cit-0010">
<collab collab-type="authors" id="dom12803-gp-0001">Food and Drug Administration</collab>
. <article-title>Inactive ingredient search for approved drug products</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm">http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm</ext-link>. Accessed October 21, 2016.</mixed-citation></ref><ref id="dom12803-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12803-cit-0011">
<string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>H&#x000f6;velmann</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Br&#x000f8;ndsted</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Adrian</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Nosek</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Haahr</surname>
<given-names>H</given-names>
</string-name>. <article-title>Faster&#x02010;acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart</article-title>. <source>Diabetes Obes Metab</source>. <year>2015</year>;<volume>17</volume>:<fpage>682</fpage>&#x02010;<lpage>688</lpage>.<pub-id pub-id-type="pmid">25846340</pub-id></mixed-citation></ref><ref id="dom12803-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12803-cit-0012">
<string-name>
<surname>Radermecker</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Scheen</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Continuous subcutaneous insulin infusion with short&#x02010;acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost&#x02010;effectiveness</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2004</year>;<volume>20</volume>:<fpage>178</fpage>&#x02010;<lpage>188</lpage>.<pub-id pub-id-type="pmid">15133748</pub-id></mixed-citation></ref><ref id="dom12803-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12803-cit-0013">
<string-name>
<surname>Bode</surname>
<given-names>BW</given-names>
</string-name>. <article-title>Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid&#x02010;acting insulin analogues&#x02010;aspart, lispro and glulisine</article-title>. <source>Endocr Pract</source>. <year>2011</year>;<volume>17</volume>:<fpage>271</fpage>&#x02010;<lpage>280</lpage>.<pub-id pub-id-type="pmid">21134878</pub-id></mixed-citation></ref><ref id="dom12803-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12803-cit-0014">
<string-name>
<surname>Benesch</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Heinemann</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Arnolds</surname>
<given-names>S</given-names>
</string-name>. <article-title>How to assess the quality of glucose clamps? Evaluation of clamps performed with ClampArt, a novel automated clamp device</article-title>. <source>J Diabetes Sci Technol</source>. <year>2015</year>;<volume>9</volume>:<fpage>792</fpage>&#x02010;<lpage>800</lpage>.<pub-id pub-id-type="pmid">25852075</pub-id></mixed-citation></ref><ref id="dom12803-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12803-cit-0015">
<collab collab-type="authors" id="dom12803-gp-0002">American Diabetes Association</collab>
. <article-title>Defining and reporting hypoglycaemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycaemia</article-title>. <source>Diabetes Care</source>. <year>2005</year>;<volume>28</volume>:<fpage>1245</fpage>&#x02010;<lpage>1249</lpage>.<pub-id pub-id-type="pmid">15855602</pub-id></mixed-citation></ref><ref id="dom12803-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12803-cit-0016">
<string-name>
<surname>Fieller</surname>
<given-names>EC</given-names>
</string-name>. <article-title>Some problems in interval estimation</article-title>. <source>J R Stat Soc Series B Stat Methodol</source>. <year>1954</year>;<volume>16</volume>:<fpage>175</fpage>&#x02010;<lpage>185</lpage>.</mixed-citation></ref><ref id="dom12803-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom12803-cit-0017">
<string-name>
<surname>Bode</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hyveled</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tamer</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Ybanez</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Demissie</surname>
<given-names>M</given-names>
</string-name>. <article-title>Improved postprandial glycemic control with faster&#x02010;acting insulin aspart in subjects with type 1 diabetes using CSII</article-title>. <source>Diabetes</source>. <year>2015</year>;<volume>64</volume>(<issue>suppl 1</issue>):<fpage>A253</fpage> (Poster 994&#x02010;P).</mixed-citation></ref><ref id="dom12803-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom12803-cit-0018">
<string-name>
<surname>Monnier</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lapinski</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Colette</surname>
<given-names>C</given-names>
</string-name>. <article-title>Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)</article-title>. <source>Diabetes Care</source>. <year>2003</year>;<volume>26</volume>:<fpage>881</fpage>&#x02010;<lpage>885</lpage>.<pub-id pub-id-type="pmid">12610053</pub-id></mixed-citation></ref><ref id="dom12803-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom12803-cit-0019">
<string-name>
<surname>Wang</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Tu</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>IT</given-names>
</string-name>, et al. <article-title>Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2011</year>;<volume>27</volume>:<fpage>79</fpage>&#x02010;<lpage>84</lpage>.<pub-id pub-id-type="pmid">21218511</pub-id></mixed-citation></ref><ref id="dom12803-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom12803-cit-0020">
<string-name>
<surname>Riddle</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Umpierrez</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>DiGenio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>. <article-title>Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2011</year>;<volume>34</volume>:<fpage>2508</fpage>&#x02010;<lpage>2514</lpage>.<pub-id pub-id-type="pmid">22028279</pub-id></mixed-citation></ref><ref id="dom12803-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom12803-cit-0021">
<string-name>
<surname>Russell&#x02010;Jones</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>de Block</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Double&#x02010;blind mealtime faster&#x02010;acting insulin aspart vs insulin aspart in basal&#x02013;bolus improves glycemic control in T1D: the onset&#x000ae; 1 trial</article-title>. <source>Diabetes</source>. <year>2016</year>;<volume>65</volume>(<issue>suppl 1</issue>):<fpage>A77</fpage>.</mixed-citation></ref><ref id="dom12803-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dom12803-cit-0022">
<string-name>
<surname>Cengiz</surname>
<given-names>E</given-names>
</string-name>. <article-title>Closer to ideal insulin action: ultra fast acting insulins</article-title>. <source>Panminerva Med</source>. <year>2013</year>;<volume>55</volume>:<fpage>269</fpage>&#x02010;<lpage>275</lpage>.<pub-id pub-id-type="pmid">24088800</pub-id></mixed-citation></ref><ref id="dom12803-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom12803-cit-0023">
<string-name>
<surname>Maahs</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Horton</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Chase</surname>
<given-names>HP</given-names>
</string-name>. <article-title>The use of insulin pumps in youth with type 1 diabetes</article-title>. <source>Diabetes Technol Ther</source>. <year>2010</year>;<volume>12</volume>:<fpage>S59</fpage>&#x02010;<lpage>S65</lpage>.<pub-id pub-id-type="pmid">20515309</pub-id></mixed-citation></ref><ref id="dom12803-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom12803-cit-0024">
<string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Haahr</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>L</given-names>
</string-name>, Erichsen L, Hompesch M. <article-title>Faster&#x02010;acting insulin aspart improves postprandial glycemia vs insulin aspart in patients with type 1 diabetes mellitus (T1DM)</article-title>. <source>Diabetes</source>. <year>2014</year>;<volume>63</volume>(<issue>suppl 1</issue>):<fpage>A34</fpage>.</mixed-citation></ref><ref id="dom12803-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dom12803-cit-0025">
<string-name>
<surname>Bell</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Smart</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Steil</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Brand&#x02010;Miller</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>King</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wolpert</surname>
<given-names>HA</given-names>
</string-name>. <article-title>Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era</article-title>. <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>:<fpage>1008</fpage>&#x02010;<lpage>1015</lpage>.<pub-id pub-id-type="pmid">25998293</pub-id></mixed-citation></ref><ref id="dom12803-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="dom12803-cit-0026">
<string-name>
<surname>Buckley</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Kildegaard</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>H&#x000f8;iberg&#x02010;Nielsen</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Mechanistic analysis into the mode(s) of action of niacinamide in faster&#x02010;acting insulin aspart</article-title>. <source>Diabetes Technol Ther</source>. <year>2016</year>;<volume>18</volume>(<issue>suppl 1</issue>):<fpage>A116</fpage>&#x02010;<lpage>A117</lpage>.</mixed-citation></ref><ref id="dom12803-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dom12803-cit-0027">
<string-name>
<surname>Regittnig</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Urschitz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lehki</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Absorption kinetics of insulin following subcutaneous bolus administration with different bolus durations</article-title>. <source>Diabetes</source>. <year>2013</year>;<volume>62</volume>(<issue>suppl 1</issue>):<fpage>A247</fpage> (Poster 966&#x02010;P).</mixed-citation></ref><ref id="dom12803-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="dom12803-cit-0028">
<string-name>
<surname>Jain</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Parks</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Sahajwalla</surname>
<given-names>C</given-names>
</string-name>. <article-title>Determination of time to onset and rate of action of insulin products: importance and new approaches</article-title>. <source>J Pharm Sci</source>. <year>2013</year>;<volume>102</volume>:<fpage>271</fpage>&#x02010;<lpage>279</lpage>.<pub-id pub-id-type="pmid">23132625</pub-id></mixed-citation></ref><ref id="dom12803-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="dom12803-cit-0029">
<string-name>
<surname>Swinnen</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Holleman</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>DeVries</surname>
<given-names>JH</given-names>
</string-name>. <article-title>The interpretation of glucose clamp studies of long&#x02010;acting insulin analogues: from physiology to marketing and back</article-title>. <source>Diabetologia</source>. <year>2008</year>;<volume>51</volume>:<fpage>1790</fpage>&#x02010;<lpage>1795</lpage>.<pub-id pub-id-type="pmid">18670752</pub-id></mixed-citation></ref></ref-list></back></article>